Dr. Matthew Mei, MD
Claim this profileCity of Hope Medical Center
Area of expertise
Hodgkin's Lymphoma
Matthew Mei, MD has run 7 trials for Hodgkin's Lymphoma. Some of their research focus areas include:
Non-Hodgkin's Lymphoma
Matthew Mei, MD has run 5 trials for Non-Hodgkin's Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
City Of Hope Medical Center
City Of Hope National Medical Center
Clinical Trials Matthew Mei, MD is currently running
Mosunetuzumab + Polatuzumab Vedotin
for Follicular Lymphoma
This phase II trial tests how well mosunetuzumab and polatuzumab vedotin works in treating patients with grade 1-3a follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Giving mosunetuzumab and polatuzumab vedotin may kill more cancer cells in patients with relapsed or refractory grade 1-3a follicular lymphoma.
Recruiting
1 award
Phase 2
6 criteria
Nivolumab + ASTX727
for B-Cell Lymphoma
This trial tests a combination of nivolumab and ASTX727 in patients with B-cell lymphoma that has come back or is not responding to treatment. Nivolumab helps the immune system attack cancer, while ASTX727 enhances the effectiveness of another drug. The goal is to find a safe and effective dose for these patients.
Recruiting
1 award
Phase 1
10 criteria
More about Matthew Mei, MD
Clinical Trial Related
13 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Matthew Mei, MD has experience with
- Nivolumab
- CD30.CAR-T
- Mosunetuzumab
- Polatuzumab Vedotin
- CC-486
- Tafasitamab
Breakdown of trials Matthew Mei, MD has run
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Lymphoma
Central Nervous System Hodgkin Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Mei, MD specialize in?
Matthew Mei, MD focuses on Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Hodgkin's Lymphoma has involved CD30 positive patients, or patients who are MYC positive.
Is Matthew Mei, MD currently recruiting for clinical trials?
Yes, Matthew Mei, MD is currently recruiting for 2 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Matthew Mei, MD has studied deeply?
Yes, Matthew Mei, MD has studied treatments such as Nivolumab, CD30.CAR-T, Mosunetuzumab.
What is the best way to schedule an appointment with Matthew Mei, MD?
Apply for one of the trials that Matthew Mei, MD is conducting.
What is the office address of Matthew Mei, MD?
The office of Matthew Mei, MD is located at: City of Hope Medical Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.